This study is looking at whether an intranasal (nose spray) of oxytocin can help people with obstructive sleep apnea (OSA) who use a CPAP machine. Researchers want to see if oxytocin can reduce the amount of pressure your CPAP machine needs to keep your airway open while you sleep. This could potentially lessen the harmful effects of low oxygen. You may be able to join if you are 18 or older, use a CPAP machine for OSA, and are not pregnant or breastfeeding. The main goal is to see how oxytocin changes the pressure needed from your auto-CPAP machine after 5 weeks. The current recruitment status is unclear.

Study design

This is a rigorous randomized, double-blinded, cross-over study involving 40 participants. This means participants will receive both oxytocin and a placebo at different times, and neither you nor the researchers will know which you are receiving.

What's involved

You would spend three nights in a sleep lab at George Washington University and use either oxytocin or a placebo nasal spray for two weeks each, with a one-week break in between. The study lasts 35 nights.

Compensation

There are no additional costs to participants and no compensation for being involved in the study.

Follow-up

The primary endpoint is measured at 5 weeks, which suggests a follow-up period of at least that long after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.